CDC NEWS


powered by Surfing Waves


Latest News


AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis


23 Mar 2021

79% vaccine efficacy at preventing symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalization Comparable efficacy result across ethnicity and age, with 80% efficacy in participants aged 65 years and over Favorable reactogenicity and overall safety profile


Experts Discuss COVID-19—Vaccine Questions, School Openings, and More


17 Mar 2021

JAMA Live Highlights features comments from livestream interviews by JAMA Network Editor in Chief Howard Bauchner, MD. His discussions with experts in clinical care, public health, and health policy focus on critical issues related to the COVID-19 pandemic. Comments have been edited for clarity.


CDC Interim Recommendations for Fully Vaccinated People


10 Mar 2021

On December 11, 2020, the US reached an extraordinary milestone in the efforts to end the COVID-19 pandemic: the Food and Drug Administration authorized emergency use of the first COVID-19 vaccine, manufactured by Pfizer-BioNTech. Since then, 2 additional COVID-19 vaccines, Moderna and Janssen (Johnson & Johnson), have received Emergency Use Authorization in the US and, as of March 8, 2021, more than 31 million people, or 9.4% of the total population, have completed a vaccination series.


Approaches for Optimal Use of Different COVID-19 Vaccines Issues of Viral Variants and Vaccine Efficacy


04 Mar 2021

The efforts of the Biden administration to accelerate rollout of COVID-19 vaccines are enabling more adults in the US to be vaccinated each week. As of February 28, 2021, an estimated more than 48 million people have received at least 1 vaccine dose.


How the Johnson & Johnson Vaccine Works


28 Feb 2021

Johnson & Johnson is testing a coronavirus vaccine known as JNJ-78436735 or Ad26.COV2.S. Clinical trials showed that a single dose of the vaccine had an efficacy rate of up to 72 percent. The vaccine has been authorized for emergency use in the United States and Bahrain.




Articles


Moderna CEO: Vaccine Will Likely Work for 'a Couple of Years'


07 Jan 2021

The Moderna vaccine ― one of two vaccines now being distributed in the United States ― will "potentially" provide protection against COVID-19 for several years, the biotech company's CEO said, according to Reuters.




Over Half of COVID Transmission May Occur via Asymptomatic People


07 Jan 2021

As COVID-19 cases surge and vaccinations lag, health authorities continue to seek additional ways to mitigate the spread of the novel coronavirus.




SARS-CoV-2 Transmission From People Without COVID-19 Symptoms


07 Jan 2021

IMPORTANCE Severeacuterespiratorysyndromecoronavirus2(SARS-CoV-2),theetiologyof coronavirus disease 2019 (COVID-19), is readily transmitted person to person. Optimal control of COVID-19 depends on directing resources and health messaging to mitigation efforts that are most likely to prevent transmission, but the relative importance of such measures has been disputed.




Sorting Out Whether Vitamin D Deficiency Raises COVID-19 Risk


06 Jan 2021

One of the risk factors du jour for coronavirus disease 2019 (COVID- 19) has been vitamin D deficiency.




Emergence of a Highly Fit SARS-CoV-2 Variant


31 Dec 2020

Sarbecoviruses have emerged twice in the 21st century, causing a worldwide epidemic and pandemic.




Enroll for Free